Company markets unique approach to managing pharma supply chains
Hot on the heels of announcing that a Covid-19 manufacturer is a client, the Santa Clara, CA, data-services firm Roambee has announced a new (“Series B1”) funding round of $18 million, and an intention to undergo another funding round later this spring.
As to the client, Roambee only says that it is “one of the largest US-based vaccine makers,” and that it is one of 300 global enterprises that are clients, across a variety of industries but concentrated in food distribution, automotive, consumer electronics, chemicals and life sciences. It also counts DHL, Kuehne+Nagel and CEVA Logistics—all major freight forwarders for pharma—as partners and clients.
There are quite a few IT or data services companies that offer to manage pharma supply chains; what makes Roambee’s approach different? According to Sanjay Sharma, CEO, the company has developed its own sensor/datalogger hardware in addition to the tracking and analytics software—and provides these as a self-service, managed-services, or platform-as-a-service (PAAS) offering. For self-service, a company acquires a volume of sensors on a fixed monthly subscription, and uses them for as many supply-chain movements as they choose. For managed services, cost is on a per-trip basis; and for PAAS, the Roambee service can be white-labeled, and its sensors combined with a client’s sensor or datalogger choices.
For a pharma manufacturer shipping its products, the service can be integrated, via APIs, with the various data-collection systems offered by logistics companies, security or packaging vendors and others, once the manufacturer provides the subscriber access to any services it uses.
Sharma recently authored a blogpost noting how one of its pharma clients had the problem of its transportation group driving toward lowest-cost service, while its logistics group was driving toward most reliable, failure-proof service, creating cost and performance conflicts. Integrating the two functions’ goals and standards enable lower-cost yet highly reliable supply chain execution, Sharma believes.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.